231 related articles for article (PubMed ID: 24926885)
21. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
23. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
24. Regulation of cell migration via the EGFR signaling pathway in oral squamous cell carcinoma cells.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Oncol Lett; 2017 Feb; 13(2):930-936. PubMed ID: 28356980
[TBL] [Abstract][Full Text] [Related]
25. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success.
Hartmann S; Kriegebaum U; Küchler N; Lessner G; Brands RC; Linz C; Schneider T; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2013 Oct; 41(7):623-9. PubMed ID: 23375534
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas.
Yin J; Jung JE; Choi SI; Kim SS; Oh YT; Kim TH; Choi E; Lee SJ; Kim H; Kim EO; Lee YS; Chang HJ; Park JY; Kim Y; Yun T; Heo K; Kim YJ; Kim H; Kim YH; Park JB; Choi SW
Cancer Lett; 2018 Feb; 414():181-189. PubMed ID: 29154973
[TBL] [Abstract][Full Text] [Related]
28. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
29. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
30. EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines.
Hiraishi Y; Wada T; Nakatani K; Tojyo I; Matsumoto T; Kiga N; Negoro K; Fujita S
Pathol Oncol Res; 2008 Mar; 14(1):39-43. PubMed ID: 18347929
[TBL] [Abstract][Full Text] [Related]
31. Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling.
Chen HJ; Lin CM; Lee CY; Shih NC; Amagaya S; Lin YC; Yang JS
Int J Oncol; 2013 Aug; 43(2):629-37. PubMed ID: 23754208
[TBL] [Abstract][Full Text] [Related]
32. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
[TBL] [Abstract][Full Text] [Related]
33. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Shintani S; Kiyota A; Mihara M; Sumida T; Kayahara H; Nakashiro K; Hamakawa H
Am J Clin Oncol; 2003 Oct; 26(5):e150-6. PubMed ID: 14528090
[TBL] [Abstract][Full Text] [Related]
35. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma.
Ge H; Liu H; Fu Z; Sun Z
J Int Med Res; 2012; 40(2):455-66. PubMed ID: 22613406
[TBL] [Abstract][Full Text] [Related]
37. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
38. Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Uzawa K; Amelio AL; Kasamatsu A; Saito T; Kita A; Fukamachi M; Sawai Y; Toeda Y; Eizuka K; Hayashi F; Kato-Kase I; Sunohara M; Iyoda M; Koike K; Nakashima D; Ogawara K; Endo-Sakamoto Y; Shiiba M; Takiguchi Y; Yamauchi M; Tanzawa H
Sci Rep; 2019 Aug; 9(1):12179. PubMed ID: 31434965
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor.
Dai W; Li Y; Zhou Q; Xu Z; Sun C; Tan X; Lu L
J Oral Pathol Med; 2014 Apr; 43(4):250-7. PubMed ID: 24020947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
